english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Lenacapavir (Sunlenca°) in multidrug-resistant HIV-1 infection

1 October 2023

Cannabidiol: sometimes serious adverse effects, and multiple drug interactions

1 October 2023

Drug shortages: patients lose out, healthcare professionals waste time

1 October 2023

Prescrire: a cosignatory of letters to various European institutions

 Advancing Healthcare Policy  In late 2022, Prescrire was a cosignatory of letters to three institutions in Europe: the Council of the European Union, the European Patent Office, and the European Parliament's Special Committee tasked with evaluating the handling of the covid­-19 pandemic.
1 October 2023

Publication of clinical trial protocols

 Advancing Healthcare Policy  In a joint letter to the European Medicines Agency's Management Board, Prescrire contested an Agency plan that would delay publication of the protocols of drug trials.
1 October 2023

Practicalities

 Editorial  A drug is more than just an active substance mixed with excipients. There is more to consider than its pharmacological properties or its economic success. A drug is also a physical product that is part of the patient's daily life. And its packaging components, such as its box, the blister packs, bottle, vial or syringe, and the patient leaflet, are an integral part of this.
1 September 2023

Nivolumab (Opdivo°) in advanced gastric or oesophageal cancer

 Marketing Authorisations   Nivolumab, a monoclonal antibody directed against PD-1, has been authorised for patients with metastatic or inoperable gastric or oesophageal adenocarcinoma or squamous cell carcinoma. In these situations, does nivolumab represent a therapeutic advance compared to the treatments already available, and, in particular, does it extend survival?
Full article (3 pages) available for download by subscribers
1 September 2023

Dulaglutide, exenatide, liraglutide and other GLP-1 receptor agonists: thyroid cancer

 Adverse Effects  In 2022, a French research team published a case-control study which investigated the association between exposure to a GLP-1 receptor agonist and the risk of developing thyroid cancer.
Full article available for download by subscribers
1 September 2023

Glucarpidase (Voraxaze°) for high-dose methotrexate toxicity

 Marketing Authorisations   Glucarpidase has been granted marketing authorisation in the European Union for reducing plasma concentrations of methotrexate in patients who have received high-dose methotrexate for cancer treatment when elimination is delayed due to impaired renal function. In this situation, does glucarpidase reduce an excessively high plasma concentration of methotrexate? Does it limit the serious dose-dependent adverse effects of this cytotoxic drug? And what are its adverse effects?
Full article (2 pages) available for download by subscribers
1 September 2023

Prescrire's annual review of drug packaging: progress is too slow

A drug's packaging contains a set of components for use by patients, their caregivers and healthcare professionals. It is important that packaging is well designed with a view to ease of use and the prevention of errors with dangerous consequences.
Full article (4 page) available for download (free)
1 September 2023

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90